ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag tuberculosis biotech clinical trials pharma fda

Opinion: On the Up and Up
Sean E. Harper | Jun 20, 2012 | 2 min read
An Amgen executive refutes accusations that the company published misleading results of its mid-90s clinical trial testing an anemia drug.
Lazarus Drugs
Kate Yandell | Feb 1, 2015 | 8 min read
While some drugs sail through development, others suffer setbacks, including FDA rejections, before reaching the market.
 
How Vesselon Can Improve the Entire Class of Antibody-Drug Conjugates
Clayton Larsen - President & CEO, Vesselon, Inc. | Oct 30, 2023 | 4 min read
Vesselon’s novel co-formulation of gas lipid microspheres and self-assembling liposomes, targeted and activated by commercial ultrasound, would be an ideal adjunct to any of these ADC drugs.
Cannabis Biotech
Daniel Cossins | Dec 1, 2014 | 8 min read
As medical marijuana businesses set up shop across the U.S., a handful of companies are taking the pharmaceutical route, guiding cannabis-derived drugs through clinical trials.
Clinical Trial Reversals Forcing Biotech Firms To Refine Strategy
Susan Dickinson | Sep 18, 1994 | 7 min read
Under pressure to reap return on investment, companies are seeking ways to ensure success in designing drug tests This past July, Synergen Inc. suspended clinical trials of its anti-inflammatory drug candidate, Antril--being tested to fight sepsis--for lack of efficacy. Faced with the setback to its $100 million-plus investment, the Boulder, Colo.-based biotech was forced to lay off more than half its work force and shut down two
Clinical Trial Reversals Forcing Biotech Firms To Refine Strategy
Susan Dickinson | Sep 18, 1994 | 7 min read
Under pressure to reap return on investment, companies are seeking ways to ensure success in designing drug tests This past July, Synergen Inc. suspended clinical trials of its anti-inflammatory drug candidate, Antril--being tested to fight sepsis--for lack of efficacy. Faced with the setback to its $100 million-plus investment, the Boulder, Colo.-based biotech was forced to lay off more than half its work force and shut down two
2022 Top 10 Innovations 
2022 Top 10 Innovations
The Scientist | Dec 12, 2022 | 10+ min read
This year’s crop of winning products features many with a clinical focus and others that represent significant advances in sequencing, single-cell analysis, and more.
Biotech-Big Pharma Betrothals Declining
Sam Jaffe | Jul 7, 2002 | 5 min read
You've just started your job with a small biotech startup that has some promising drug candidates and a freewheeling culture. You enjoy the shorts and T-shirt dress code and the midnight pizza parties for late workers, as well as the generous stock options. But then it's announced that your company has sold a large equity stake to a mega-pharmaceutical company. Now you're expected to wear a suit when meeting with your partners. To make matters worse, the large equity stake the pharma company
The Companies that Failed
Edyta Zielinska | Dec 20, 2011 | 3 min read
A roundup of eight biotech companies that didn’t make it through this year's continuing tough economic times
The Tribulations of Clinical Trials
Susan Warner | Apr 25, 2004 | 10+ min read
PictureQuestA plain tablet in a no-name blisterpack. It could save a life.Or maybe not.Since 1994, the Food and Drug Administration has approved year-to-year increases in the number of new candidate drugs for human testing in the United States, rising from 3,350 in 1996 to 3,900 in 2002.1 But the number of drugs that successfully negotiate the trial process and ultimately receive FDA approval is frustratingly low. Despite pharmaceutical companies' and the National Institutes of Health's research

Run a Search

ADVERTISEMENT